Anticoagulation Treatment in Cancer-Associated Venous Thromboembolism: Assessment of Patient Preferences Using a Discrete Choice Experiment (COSIMO Study)

Thromb Haemost. 2021 Feb;121(2):206-215. doi: 10.1055/s-0040-1714739. Epub 2020 Sep 2.

Abstract

Introduction: Clinical guidelines recommend anticoagulation therapy for the treatment of cancer-associated venous thromboembolism (VTE), but little is known about preferences. Therefore, the objective of this discrete choice experiment (DCE) was to elucidate patient preferences regarding anticoagulation convenience attributes.

Methods: Adult patients with cancer-associated VTE who switched to direct oral anticoagulants were included in a single-arm study (COSIMO). Patients were asked to decide between hypothetical treatment options based on a combination of the following attributes: route of administration (injection/tablet), frequency of intake (once/twice daily), need for regular controls of the international normalized ratio (INR) at least every 3 to 4 weeks (yes/no), interactions with food/alcohol (yes/no), and distance to treating physician (1 vs. 20 km) as an additional neutral attribute. DCE data were collected by structured telephone interviews and analyzed based on a conditional logit regression.

Results: Overall, 163 patients (mean age 63.7 years, 49.1% female) were included. They strongly preferred oral administration compared with self-injections (importance of this attribute for overall treatment decisions: 73.8%), and a treatment without dietary restrictions (11.8%). Even if these attributes were less important (7.2% and 6.5%, respectively), patients indicated a preference for a shorter distance to the treating physician and once-daily dosing compared with twice-daily intake. "Need for regular controls of INR at least every 3 to 4 weeks" showed no significant impact on the treatment decision (0.7%).

Conclusion: This study showed that treatment-related decision making in cancer-associated VTE, assuming comparable effectiveness and safety of anticoagulant treatments, is predominantly driven by "route of administration," with patients strongly preferring oral administration.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use*
  • Drug Administration Routes
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasms / complications*
  • Patient Preference
  • Prospective Studies
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / etiology*

Substances

  • Anticoagulants

Grants and funding

Funding This study was funded by Bayer AG. This work has been supported by the Italian Ministry of Health Ricerca Corrente - IRCCS MultiMedica.